The inhibitory checkpoint, PD-L2, is a target for effector T cells: Novel possibilities for immune therapy.

导出 LinkOut

翻译打印收藏纠错

作者： Shamaila Munir,Ahmad ^[1] ; Evelina,Martinenaite ^[1] ; Morten,Holmström ^[1] ; Mia Aaboe,Jørgensen ^[2] ; Özcan,Met ^[1] ; Claudia,Nastasi ^[1] ; Uffe,Klausen ^[3] ; Marco,Donia ^[4] ; Lars Møller,Pedersen ^[4] ; Lars,Munksgaard ^[1] ; Niels,Ødum ^[1] ; Anders,Woetmann ^[3] ; Inge Marie,Svane ^[5] ; Mads Hald,Andersen ^[2]

作者单位： Center for Cancer Immune Therapy (CCIT), Department of Hematology, Copenhagen University Hospital, Herlev, DK-2730 Herlev, Denmark. ^[1] Department of Hematology, Zealand University Hospital, DK-4000 Roskilde, Denmark. ^[2] Department of Oncology, Copenhagen University Hospital, Herlev, DK-2730 Herlev, Denmark. ^[3] Department of Immunology and Microbiology, University of Copenhagen, Copenhagen, Denmark. ^[4] Department of hematology, Copenhagen University Hospital, Herlev, DK-2730 Herlev, Denmark. ^[5]

关键词 Anti-cancer immunity CD4+ T cells CD8+ T cells Immune checkpoint regulator PD-L2

DOI 10.1080/2162402X.2017.1390641

PMID 29308318

发布时间 2021-01-12

翻译满意度评价：

准确一般字义偏差语意偏离译文作用小提交

浏览10

Oncoimmunology

e1390641页

相似文献

中文期刊
外文期刊
学位论文
会议论文

检索历史清除

The inhibitory checkpoint, PD-L2, is a target for effector T cells: Novel possibilities for immune therapy.

Oncoimmunology

相似文献

Oncoimmunology

相关期刊

参考文献：
指定格式：	NoteExpress EndNote RefWorks NoteFirst

检索历史 清除

The inhibitory checkpoint, PD-L2, is a target for effector T cells: Novel possibilities for immune therapy.

Oncoimmunology

相似文献

Oncoimmunology

相关期刊

检索历史清除